Neoadjuvant radiotherapeutic strategies in pancreatic cancer

Abstract

This review summarizes the current status of neoadjuvant radiation approaches in the treatment of pancreatic cancer, including a description of modern radiation techniques, and an overview on the literature regarding neoadjuvant radio- or radiochemotherapeutic strategies both for resectable and irresectable pancreatic cancer. Neoadjuvant chemoradiation for locally-advanced, primarily non- or borderline resectable pancreas cancer results in secondary resectability in a substantial proportion of patients with consecutively markedly improved overall prognosis and should be considered as possible alternative in pretreatment multidisciplinary evaluations. In resectable pancreatic cancer, outstanding results in terms of response, local control and overall survival have been observed with neoadjuvant radio- or radiochemotherapy in several phase I/II trials, which justify further evaluation of this strategy. Further investigation of neoadjuvant chemoradiation strategies should be performed preferentially in randomized trials in order to improve comparability of the current results with other treatment modalities. This should include the evaluation of optimal sequencing with newer and more potent systemic induction therapy approaches. Advances in patient selection based on new molecular markers might be of crucial interest in this context. Finally modern external beam radiation techniques (intensity-modulated radiation therapy, image-guided radiation therapy and stereotactic body radiation therapy), new radiation qualities (protons, heavy ions) or combinations with alternative boosting techniques widen the therapeutic window and contribute to the reduction of toxicity.

Keywords: Pancreatic cancer, Neoadjuvant, Radiation therapy, Review, Radiation techniques

Core tip: This review summarizes the current status of neoadjuvant radiation approaches for pancreatic cancer. Neoadjuvant chemoradiation for locally-advanced cases results in secondary resectability in a substantial proportion of patients with consecutively improved overall prognosis. In resectable pancreatic cancer, outstanding results in terms of response, local control and overall survival have been observed in several phase I/II trials. Further investigation of neoadjuvant chemoradiation strategies should be performed preferentially in randomized trials and included evaluation of optimal sequencing with chemotherapy and patient selection based on molecular markers. Modern radiation techniques widen the therapeutic window and contribute to the reduction of toxicity.